FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809679372> ?p ?o ?g. }

• W2809679372 endingPage "1065" @default.
• W2809679372 startingPage "1058" @default.
• W2809679372 abstract "Combined daclatasvir (DCV)/asunaprevir (ASV) plus beclabuvir (BCV) treatment shows a high virological response for genotype 1b chronic hepatitis C patients. However, its efficacy for patients for whom previous direct-acting antiviral (DAA) therapy failed is not known. We analysed the efficacy of DCV/ASV/BCV treatment for HCV-infected mice and chronic hepatitis patients. Human hepatocyte chimaeric mice were injected with serum samples obtained from either a DAA-naïve patient or a DCV/ASV treatment failure and were then treated with DCV/ASV alone or in combination with BCV for 4 weeks. DCV/ASV treatment successfully eliminated the virus in DAA-naïve-patient HCV-infected mice. DCV/ASV treatment failure HCV-infected mice developed viral breakthrough during DCV/ASV treatment, with the emergence of NS5A-L31V/Y93H HCV resistance-associated variants (RAVs) being observed by direct sequencing. DCV/ASV/BCV treatment inhibited viral breakthrough in NS5A-L31V/Y93H-mutated HCV-infected mice, but HCV relapsed with the emergence of NS5B-P495S variants after the cessation of the treatment. The efficacy of the triple therapy was also analysed in HCV-infected patients; one DAA-naïve patient and four prior DAA treatment failures were treated with 12 weeks of DCV/ASV/BCV therapy. Sustained virological response was achieved in a DAA-naïve patient and one of the DCV/ASV treatment failures through DCV/ASV/BCV therapy; however, HCV relapse occurred in the other patients with prior DCV/ASV and/or sofosbuvir/ledipasvir treatment failures. DCV/ASV/BCV therapy seems to have limited efficacy for patients with NS5A RAVs for whom prior DAA treatment has failed." @default.
• W2809679372 created "2018-06-29" @default.
• W2809679372 creator A5002799579 @default.
• W2809679372 creator A5008377317 @default.
• W2809679372 creator A5021393447 @default.
• W2809679372 creator A5022484621 @default.
• W2809679372 creator A5022592264 @default.
• W2809679372 creator A5024182187 @default.
• W2809679372 creator A5027424189 @default.
• W2809679372 creator A5027695992 @default.
• W2809679372 creator A5035574974 @default.
• W2809679372 creator A5044269436 @default.
• W2809679372 creator A5050462385 @default.
• W2809679372 creator A5053839162 @default.
• W2809679372 creator A5054427357 @default.
• W2809679372 creator A5063059796 @default.
• W2809679372 creator A5070035943 @default.
• W2809679372 creator A5089353704 @default.
• W2809679372 date "2018-08-01" @default.
• W2809679372 modified "2023-09-27" @default.
• W2809679372 title "Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure" @default.
• W2809679372 cites W1510051491 @default.
• W2809679372 cites W1551301313 @default.
• W2809679372 cites W1804925654 @default.
• W2809679372 cites W1807436464 @default.
• W2809679372 cites W1972821220 @default.
• W2809679372 cites W1977300462 @default.
• W2809679372 cites W2005895808 @default.
• W2809679372 cites W2010380636 @default.
• W2809679372 cites W2017347114 @default.
• W2809679372 cites W2060755598 @default.
• W2809679372 cites W2087386621 @default.
• W2809679372 cites W2101598010 @default.
• W2809679372 cites W2166143354 @default.
• W2809679372 cites W2183618944 @default.
• W2809679372 cites W2318156787 @default.
• W2809679372 cites W2400309615 @default.
• W2809679372 cites W2463921556 @default.
• W2809679372 cites W2478752051 @default.
• W2809679372 cites W2509341154 @default.
• W2809679372 cites W2521950197 @default.
• W2809679372 cites W2552544908 @default.
• W2809679372 cites W2585721605 @default.
• W2809679372 cites W2589381048 @default.
• W2809679372 cites W2732570732 @default.
• W2809679372 cites W2750060262 @default.
• W2809679372 cites W2761531030 @default.
• W2809679372 cites W2766054212 @default.
• W2809679372 cites W632840926 @default.
• W2809679372 doi "https://doi.org/10.1099/jgv.0.001091" @default.
• W2809679372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29916799" @default.
• W2809679372 hasPublicationYear "2018" @default.
• W2809679372 type Work @default.
• W2809679372 sameAs 2809679372 @default.
• W2809679372 citedByCount "7" @default.
• W2809679372 countsByYear W28096793722018 @default.
• W2809679372 countsByYear W28096793722019 @default.
• W2809679372 countsByYear W28096793722020 @default.
• W2809679372 countsByYear W28096793722021 @default.
• W2809679372 crossrefType "journal-article" @default.
• W2809679372 hasAuthorship W2809679372A5002799579 @default.
• W2809679372 hasAuthorship W2809679372A5008377317 @default.
• W2809679372 hasAuthorship W2809679372A5021393447 @default.
• W2809679372 hasAuthorship W2809679372A5022484621 @default.
• W2809679372 hasAuthorship W2809679372A5022592264 @default.
• W2809679372 hasAuthorship W2809679372A5024182187 @default.
• W2809679372 hasAuthorship W2809679372A5027424189 @default.
• W2809679372 hasAuthorship W2809679372A5027695992 @default.
• W2809679372 hasAuthorship W2809679372A5035574974 @default.
• W2809679372 hasAuthorship W2809679372A5044269436 @default.
• W2809679372 hasAuthorship W2809679372A5050462385 @default.
• W2809679372 hasAuthorship W2809679372A5053839162 @default.
• W2809679372 hasAuthorship W2809679372A5054427357 @default.
• W2809679372 hasAuthorship W2809679372A5063059796 @default.
• W2809679372 hasAuthorship W2809679372A5070035943 @default.
• W2809679372 hasAuthorship W2809679372A5089353704 @default.
• W2809679372 hasBestOaLocation W28096793721 @default.
• W2809679372 hasConcept C159047783 @default.
• W2809679372 hasConcept C2522874641 @default.
• W2809679372 hasConcept C2775999097 @default.
• W2809679372 hasConcept C2776408679 @default.
• W2809679372 hasConcept C2776979040 @default.
• W2809679372 hasConcept C2777103181 @default.
• W2809679372 hasConcept C2778390639 @default.
• W2809679372 hasConcept C2780040827 @default.
• W2809679372 hasConcept C2781463415 @default.
• W2809679372 hasConcept C71924100 @default.
• W2809679372 hasConcept C86803240 @default.
• W2809679372 hasConceptScore W2809679372C159047783 @default.
• W2809679372 hasConceptScore W2809679372C2522874641 @default.
• W2809679372 hasConceptScore W2809679372C2775999097 @default.
• W2809679372 hasConceptScore W2809679372C2776408679 @default.
• W2809679372 hasConceptScore W2809679372C2776979040 @default.
• W2809679372 hasConceptScore W2809679372C2777103181 @default.
• W2809679372 hasConceptScore W2809679372C2778390639 @default.
• W2809679372 hasConceptScore W2809679372C2780040827 @default.
• W2809679372 hasConceptScore W2809679372C2781463415 @default.
• W2809679372 hasConceptScore W2809679372C71924100 @default.

• next